Dr. Cree is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1500 Owens St, Suite 320
San Francisco, CA 94158Phone+1 415-353-2069Fax+1 415-353-2633- Is this information wrong?
Education & Training
- New York Presbyterian Hospital (Cornell Campus)Residency, Neurology, 1998 - 2001
- California Pacific Medical CenterInternship, Internal Medicine, 1997 - 1998
- University of California San Francisco School of MedicineClass of 1997
Certifications & Licensure
- CA State Medical License 2001 - 2024
- American Board of Psychiatry and Neurology Neurology
Awards, Honors, & Recognition
- Regional Top Doctor Castle Connolly, 2014
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Safety and Tolerability of Rituximab in Neuromyelitis Optica Start of enrollment: 2004 Jan 01
- Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis Start of enrollment: 2011 Sep 08
- Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Start of enrollment: 2016 Dec 01
- Join now to see all
Publications & Presentations
PubMed
- Choroid plexus volume differentiates MS from its mimics.Elle Levit, Zheng Ren, Virgilio Gonzenbach, Christina J Azevedo, Peter A Calabresi, Bruce Ac Cree, Leorah Freeman, Erin E Longbrake, Jiwon Oh, Matthew K Schindler, Nan...> ;Multiple Sclerosis. 2024 Mar 13
- Sphingosine 1-phosphate receptor modulators in multiple sclerosis treatment: A practical review.Freedman, M., Coyle, P., Cohen, B., Cree, B., Markowitz, C.> ;Annals of Clinical and Translational Neurology. 2024 Feb 16
- MRI of the relevant domain should be performed to confirm whether clinical symptoms represent an attack of NMOSD: No.Marignier, R., Cree, B.> ;Multiple Sclerosis. 2024 Jan 1
- Join now to see all
Lectures
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Pittsburgh, Pennsylvania - 5/4/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Cleveland, Ohio - 4/27/2013
- Optimizing the Risk-Benefit Therapeutic Equation for Multiple SclerosisCMEducation Resources, LLC, Denver, Colorado - 4/20/2013
- Join now to see all
Press Mentions
- New Analysis of MRI Findings Show Uplizna Reduced the Formation of Asymptomatic Optic Nerve Lesions in People with NMOSDMarch 15th, 2023
- New Data Suggest Uplinza for the Treatment of NMOSD Did Not Increase the Risk of COVID-19 or Reduce Antibody Levels from Childhood VaccinesFebruary 28th, 2023
- New Analysis of UPLIZNA® (Inebilizumab-Cdon) Phase 3 Trial Data Demonstrates Importance of Reducing Plasmablasts to Help Prevent Neuromyelitis Optica Spectrum Disorder (NMOSD) AttacksOctober 26th, 2022
- Join now to see all
Hospital Affiliations
- UCSF Medical CenterSan Francisco, California
- Zuckerberg San Francisco General Hospital and Trauma CenterSan Francisco, California
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: